About this episode
In What's Trending in Aesthetics? we discuss the topics doing the rounds on social media, in injector forums and in the news: the controversies, big stories and themes getting our industry talking.
In Chapter 11 (Part 1) we reflect on another new toxin arriving in the Australian market, and the clinical and financial implications for clinics. We discuss the challenges of introducing new products into your business, particularly toxins and fillers.
We highlight the importance of critically analysing clinical studies, including non-inferiority studies, communicating transparently with patients if you change their usual product, pricing strategy, and understanding the nuances of different toxin and filler products.
We also cover clinical photography, routine patient reviews, the pitfalls of packaging treatments and the perception of free top-ups, and finish with practical advice on balancing margins and cash flow. Part 2 of this episode is available exclusively in IA Community.
What you'll learn
- How to critically read clinical studies, including non-inferiority trials
- Telling patients when you change their product
- Pricing and packaging new products
- Running your own internal product trials
- Why free top-ups undermine your value
- Balancing margins and cash flow
Topics
- What's trending
- Botulinum toxin
- New products
- Pricing
- Research
- Business
Full transcript
The full transcript for this episode is coming soon.